We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Publicly Lists Healthcare Business

By Sanjit Dutt
Posted on 14 Nov 2016
Print article
Siemens AG (Munich, Germany), Europe’s largest industrial conglomerate, has announced that its USD 15 billion healthcare division, which operates under the uniform brand name Siemens Healthineers (Erlangen, Germany), will be publicly listed as an independent medical technology business.

In May 2014, Siemens had announced its intention to set up its healthcare business as a "company within the company" so that the business could adjust to transformations in the healthcare market in a flexible and focused manner with its own market presence. Siemens Healthineers focuses on the therapeutic and molecular diagnostic market, and offers medical imaging, laboratory diagnostics, and management, consulting and digital services. It is currently working with Pfizer to develop in vitro diagnostic tests for improving patient selection, treatment monitoring and dosing in clinical trials, as well as with ViiV Healthcare for developing diagnostics for its first-in-class HIV drug Celsentri (maraviroc).

Siemens has not yet provided any details about the planned scope and timing regarding the initial public offering of its healthcare business, but expects the move to encourage investors and provide a foundation for any future acquisitions or investments. "Healthcare technology is a highly attractive business in which we want to further expand our leading position. With this step, we continue to implement Vision 2020 launched in May 2014. The public listing will give Healthineers even more focus and flexibility in pursuing its growth strategy," said Joe Kaeser, President and CEO of Siemens AG. "The public listing is now the next step in further strengthening Siemens Healthineers in Siemens for the future. We're implementing this from an already leading position. Siemens Healthineers has already increased its market share and has an outstanding portfolio of top technologies that we're further developing," added Kaeser.

"The public listing is a key lever for reaching our strategic goal of being THE enabler for healthcare providers worldwide," said Bernd Montag, CEO of Siemens Healthineers. "Greater entrepreneurial freedom and agility will allow us to help shape the development of the global healthcare market and the growth strategies of successful healthcare providers. We'll enable our customers to participate successfully in the trends toward consolidation, industrialization and holistic health management with a high degree of clinical relevance, efficient workflows and financial value added."

Related Links:
Siemens
Siemens Healthineers
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB)

Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections

Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more